Adiponectin: An update

Diabetes and Metabolism

Volumn 34, Issue 1, 2008, Pages 12-18

  Guerre Millo, M ^a,b  

^a HÔTEL DIEU   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

AdipoR; AMP kinase; Metabolic diseases; Rimonabant; Thiazolidinediones

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; GLITAZONE DERIVATIVE; LEPTIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIMONABANT;

ADIPOSE TISSUE CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INFILTRATION; CIRCULATION; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FOOD INTAKE; GENE EXPRESSION REGULATION; GENE MUTATION; HEART PROTECTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER; MACROPHAGE; MACROPHAGE MIGRATION; METABOLIC DISORDER; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRUCTURE ANALYSIS; VASCULAR ENDOTHELIUM; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADENYLATE KINASE; ADIPONECTIN; ENZYME ACTIVATION; HUMANS; LIVER; MUSCLE, SKELETAL; RECEPTORS, ADIPONECTIN;

EID: 39149089305     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2007.08.002     Document Type: Review

References (87)

1. Ahima R.S., and Flier J.S. Leptin. Annu Rev Physiol 62 (2000) 413-437
2. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
3. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 (1996) 10697-10703
4. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221 (1996) 286-289
5. Nakano Y., Tobe T., Choi-Miura N.H., Mazda T., and Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120 (1996) 803-812
6. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
7. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
8. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
9. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
10. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
11. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (2002) 25863-25866
12. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277 (2002) 37487-37491
13. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
14. Yamauchi T., Kamon J., Waki H., Imai Y., Shimozawa N., Hioki K., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278 (2003) 2461-2468
15. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 (2005) 1096-1103
16. Kato H., Kashiwagi H., Shiraga M., Tadokoro S., Kamae T., Ujiie H., et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26 (2006) 224-230
17. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
18. Bouhali T, Brisson D, St Pierre J, Tremblay G, Perron P, Laprise C. et al. Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. Atherosclerosis, in press.
19. Hotta K., Funahashi T., Bodkin N.L., Ortmeyer H.K., Arita Y., Hansen B.C., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50 (2001) 1126-1133
20. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (2002) 731-737
21. Ma K., Cabrero A., Saha P.K., Kojima H., Li L., Chang B.H., et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 277 (2002) 34658-34661
22. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281 (2006) 2654-2660
23. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
24. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 (2003) 226-228
25. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
26. Wang Y., Xu L.Y., Lam K.S., Lu G., Cooper G.J., and Xu A. Proteomic characterization of human serum proteins associated with the fat-derived hormone adiponectin. Proteomics 6 (2006) 3862-3870
27. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98 (2001) 2005-2010
28. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
29. Wong G.W., Wang J., Hug C., Tsao T.S., and Lodish H.F. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A 101 (2004) 10302-10307
30. Hara K., Horikoshi M., Yamauchi T., Yago H., Miyazaki O., Ebinuma H., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29 (2006) 1357-1362
31. Ebinuma H., Miyazaki O., Yago H., Hara K., Yamauchi T., and Kadowaki T. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 372 (2006) 47-53
32. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
33. Combs T.P., Berg A.H., Obici S., Scherer P.E., and Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108 (2001) 1875-1881
34. Bajaj M., Suraamornkul S., Piper P., Hardies L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89 (2004) 200-206
35. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L.J., and DeFronzo R.A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89 (2004) 4312-4319
36. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90 (2005) 3498-3504
37. Kahn B.B., Alquier T., Carling D., and Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 (2005) 15-25
38. Kola B., Boscaro M., Rutter G.A., Grossman A.B., and Korbonits M. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 17 (2006) 205-215
39. Viollet B., Foretz M., Guigas B., Horman S., Dentin R., Bertrand L., et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 574 (2006) 41-53
40. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
41. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang C.C., Itani S.I., et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 99 (2002) 16309-16313
42. Civitarese A.E., Ukropcova B., Carling S., Hulver M., DeFronzo R.A., Mandarino L., et al. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 4 (2006) 75-87
43. Andreelli F., Foretz M., Knauf C., Cani P.D., Perrin C., Iglesias M.A., et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147 (2006) 2432-2441
44. Ouchi N., Kobayashi H., Kihara S., Kumada M., Sato K., Inoue T., et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279 (2004) 1304-1309
45. Shibata R., Ouchi N., Kihara S., Sato K., Funahashi T., and Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 279 (2004) 28670-28674
46. Kobayashi H., Ouchi N., Kihara S., Walsh K., Kumada M., Abe Y., et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94 (2004) e27-e31
47. Chen H., Montagnani M., Funahashi T., Shimomura I., and Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278 (2003) 45021-45026
48. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278 (2003) 40352-40363
49. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
50. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13 (2007) 332-339
51. Mao X., Kikani C.K., Riojas R.A., Langlais P., Wang L., Ramos F.J., et al. APPL1 binds to adiponectin receptors and mediates adiponectin signaling and function. Nat Cell Biol 8 (2006) 516-523
52. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., and Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 101 (2004) 10308-10313
53. Tsuchida A., Yamauchi T., Ito Y., Hada Y., Maki T., Takekawa S., et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279 (2004) 30817-30822
54. Beylot M., Pinteur C., and Peroni O. Expression of the adiponectin receptors AdipoR1 and AdipoR2 in lean rats and in obese Zucker rats. Metabolism 55 (2006) 396-401
55. Staiger H., Kaltenbach S., Staiger K., Stefan N., Fritsche A., Guirguis A., et al. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 53 (2004) 2195-2201
56. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004) 1752-1761
57. Clement K., Viguerie N., Poitou C., Carette C., Pelloux V., Curat C.A., et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18 (2004) 1657-1669
58. Cancello R., Henegar C., Viguerie N., Taleb S., Poitou C., Rouault C., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54 (2005) 2277-2286
59. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285 (2003) 527-533
60. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301 (2003) 1045-1050
61. Pietilainen K.H., Kannisto K., Korsheninnikova E., Rissanen A., Kaprio J., Ehrenborg E., et al. Acquired obesity increases CD68 and tumor necrosis factor-{alpha} and decreases adiponectin gene expression in adipose tissue: a study in monozygotic twins. J Clin Endocrinol Metab 91 (2006) 2776-2781
62. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97 (2005) 1245-1252
63. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
64. Chinetti G., Zawadski C., Fruchart J.C., and Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 314 (2004) 151-158
65. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
66. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 273-280
67. Cancello R., Tordjman J., Poitou C., Guilhem G., Bouillot J.L., Hugol D., et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55 (2006) 1554-1561
68. Kelesidis I., Kelesidis T., and Mantzoros C.S. Adiponectin and cancer: a systematic review. Br J Cancer 94 (2006) 1221-1225
69. Lara-Castro C., Luo N., Wallace P., Klein R.L., and Garvey W.T. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55 (2006) 249-259
70. Bobbert T., Rochlitz H., Wegewitz U., Akpulat S., Mai K., Weickert M.O., et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54 (2005) 2712-2719
71. Rossi A.S., Lombardo Y.B., Lacorte J.M., Chicco A.G., Rouault C., Slama G., et al. Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol 289 (2005) R486-R494
72. Flachs P., Mohamed-Ali V., Horakova O., Rossmeisl M., Hosseinzadeh-Attar M.J., Hensler M., et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 49 (2006) 394-397
73. Neschen S., Morino K., Rossbacher J.C., Pongratz R.L., Cline G.W., Sono S., et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 55 (2006) 924-928
74. Todoric J., Loffler M., Huber J., Bilban M., Reimers M., Kadl A., et al. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n - 3 polyunsaturated fatty acids. Diabetologia 49 (2006) 2109-2119
75. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
76. Combs T.P., Wagner J.A., Berger J., Doebber T., Wang W.J., Zhang B.B., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
77. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
78. Phillips S.A., Ciaraldi T.P., Kong A.P., Bandukwala R., Aroda V., Carter L., et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52 (2003) 667-674
79. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 (2003) 1655-1663
80. Tsuchida A., Yamauchi T., Takekawa S., Hada Y., Ito Y., Maki T., et al. Peroxisome proliferators activated receptor (PPAR){alpha} activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPAR{alpha}, PPAR{gamma}, and their combination. Diabetes 54 (2005) 3358-3370
81. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279 (2004) 12152-12162
82. van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
83. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
84. Scheen A.J., Finer N., Hollander P., Jensen M.D., and van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
85. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
86. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
87. Narasimhan M.L., Coca M.A., Jin J., Yamauchi T., Ito Y., Kadowaki T., et al. Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17 (2005) 171-180